Registry of Endovascular Treatment for Acute Ischemic Stroke Patients
Prospective Registry Study of Endovascular Treatment for Acute Ischemic Stroke Patients in China
This study is collecting information from patients with acute ischemic stroke who receive endovascular treatment to see how well the therapy works in real life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Zhangzhou Municipal Hospital Academic / other |
| Locations | 6 sites (Zhangzhou, Fujian and 5 other locations) |
| Trial ID | NCT05988125 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather data on the assessment, diagnosis, and treatment of patients with acute ischemic stroke who undergo endovascular therapy. It is a multicenter registry that will enroll patients from various stroke centers, collecting baseline and follow-up information at 90 days post-stroke. The data will include demographics, comorbidities, stroke severity, treatment details, and functional outcomes to better understand the real-world application of endovascular treatments.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with acute ischemic stroke and confirmed large vessel occlusion who are undergoing endovascular treatment.
Not a fit: Patients with acute intracranial hemorrhage or those without evidence of large vessel occlusion will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the understanding and management of acute ischemic stroke, leading to better patient outcomes.
How similar studies have performed: Other studies have shown success with similar observational approaches in understanding treatment outcomes for acute ischemic stroke.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Acute ischemic stroke; 2. Brain imaging confirmed intracranial large vessel occlusion: intracranial internal carotid artery (ICA), middle cerebral artery (MCA M1/M2), anterior cerebral artery (ACA A1/A2), basilar artery (BA), vertebral artery (VA V4), and posterior cerebral artery (PCA P1); 3. Initiation of any type of endovascular treatment, including mechanical thrombectomy, aspiration, angioplasty, and stenting; 4. Informed Consent as documented by signature or fulfilling the criteria for emergency consent/ deferral consent Exclusion Criteria: 1. Acute intracranial haemorrhage 2. No evidence of large vessel occlusion on digital subtraction angiography. 3. Patient bedridden or presenting from a nursing home 4. Foreseeable difficulties in follow-up due to geographic reasons (e.g. patients living abroad) -
Where this trial is running
Zhangzhou, Fujian and 5 other locations
- Zhangzhou Municipal Hospital — Zhangzhou, Fujian, China (Recruiting)
- Gansu provincial hospital of TCM — Lanzhou, Gansu, China (Recruiting)
- Jiamusi Central Hospital — Jiamusi, Heilongjiang, China (Recruiting)
- Department of Neurology, The First Affiliated Hospital of Nanchang University — Nanchang, Jiangxi, China (Recruiting)
- Songyuan Jilin Oilfield Hospital — SongYuan, Jilin, China (Recruiting)
- Shenyang First People's Hospital — Shenyang, Liaoning, China (Recruiting)
Study contacts
- Principal investigator: Wen-huo Chen, bachelor — Zhangzhou Affiliated Hospital to Fujian Medical University , Fujian ,China
- Study coordinator: Wen-huo Chen, bachelor
- Email: doctorwwenhuo@126.com
- Phone: +86-05962082582
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.